IN2012DN02577A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02577A
IN2012DN02577A IN2577DEN2012A IN2012DN02577A IN 2012DN02577 A IN2012DN02577 A IN 2012DN02577A IN 2577DEN2012 A IN2577DEN2012 A IN 2577DEN2012A IN 2012DN02577 A IN2012DN02577 A IN 2012DN02577A
Authority
IN
India
Prior art keywords
compounds
jak
pyrrolo
inhibitors
preparation
Prior art date
Application number
Other languages
English (en)
Inventor
Brad Alan Acker
Susan J Hartmann
Horng-Chih Huang
Eric Jon Jacobsen
Michele Ann Promo
Sergey Gregory Wolfson
Jin Xie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IN2012DN02577A publication Critical patent/IN2012DN02577A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2577DEN2012 2009-10-15 2010-10-01 IN2012DN02577A (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25203909P 2009-10-15 2009-10-15
PCT/IB2010/054447 WO2011045702A1 (en) 2009-10-15 2010-10-01 Pyrrolo[2,3-d] pyrimidine compounds

Publications (1)

Publication Number Publication Date
IN2012DN02577A true IN2012DN02577A (lt) 2015-08-28

Family

ID=43413616

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2577DEN2012 IN2012DN02577A (lt) 2009-10-15 2010-10-01

Country Status (28)

Country Link
US (1) US8633206B2 (lt)
EP (1) EP2488524B1 (lt)
JP (1) JP5629324B2 (lt)
KR (1) KR20120083452A (lt)
CN (1) CN102574860A (lt)
AP (1) AP2012006192A0 (lt)
AR (1) AR078635A1 (lt)
AU (1) AU2010308028A1 (lt)
CA (1) CA2776028C (lt)
CL (1) CL2012000795A1 (lt)
CO (1) CO6531451A2 (lt)
CR (1) CR20120164A (lt)
CU (1) CU20120059A7 (lt)
DO (1) DOP2012000080A (lt)
EA (1) EA201290147A1 (lt)
EC (1) ECSP12011855A (lt)
ES (1) ES2426407T3 (lt)
IL (1) IL218802A0 (lt)
IN (1) IN2012DN02577A (lt)
MA (1) MA33670B1 (lt)
MX (1) MX2012004379A (lt)
NI (1) NI201200053A (lt)
PE (1) PE20121077A1 (lt)
TN (1) TN2012000146A1 (lt)
TW (1) TWI398444B (lt)
UY (1) UY32947A (lt)
WO (1) WO2011045702A1 (lt)
ZA (1) ZA201202718B (lt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Wave Life Sciences Japan リン原子修飾核酸の合成方法
MX2011009824A (es) 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Derivados de pirimidina-diona fusionados como moduladores del trpa1.
WO2010109329A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
ES2461967T3 (es) * 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
EP2620428B1 (en) * 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 官能化核酸の合成のための方法
MX365311B (es) 2011-08-12 2019-05-29 Nissan Chemical Ind Ltd Compuestos heterocíclicos tricíclicos inhibidores de jak.
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
AU2013287630B2 (en) 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
KR102127939B1 (ko) * 2012-07-17 2020-06-29 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 선택적인 안드로겐 수용체 조절제로서의 인돌카르보니트릴
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
ES2755130T3 (es) 2013-02-08 2020-04-21 Nissan Chemical Corp Compuesto de pirrolopiridina tricíclico, e inhibidor de JAK
ME02904B (me) * 2013-02-22 2018-04-20 Pfizer DERIVATI PIROLO[2,3 -d]PIRIMIDINA KAO INHIBITORI JANUS KINAZA (JAK)
DK2991988T3 (en) 2013-05-02 2017-08-21 Hoffmann La Roche Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
CA2944433A1 (en) 2014-05-14 2015-11-19 Nissan Chemical Industries, Ltd. Tricyclic compound and jak inhibitor
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
NZ744341A (en) * 2016-02-16 2019-06-28 Zoetis Services Llc Process for preparing 7h-pyrrolo [2, 3-d] pyrimidine compounds
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
AU2019426113B2 (en) * 2019-01-30 2022-06-16 Felicamed Biotechnology Co., Ltd. JAK inhibitor and preparation method therefor
IL264854A (en) * 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
US20220380310A1 (en) * 2019-07-01 2022-12-01 Ligang Qian P2x7r antagonists
CA3152021A1 (en) * 2019-08-26 2021-03-04 Chemwerth, Inc. Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors
CN115246833A (zh) * 2021-04-27 2022-10-28 洛阳惠中兽药有限公司 一种奥拉替尼化合物及其中间体化合物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3951899A (en) * 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP4078074B2 (ja) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ[2,3−d]ピリミジン化合物
CN100351253C (zh) * 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3-d]嘧啶化合物
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
PL377791A1 (pl) 2002-11-21 2006-02-20 Pfizer Products Inc. Pochodne 3-aminopiperydyny i sposoby ich wytwarzania
CA2536954C (en) * 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
JP2007511596A (ja) 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク 癌の治療において有用なピロロピリミジン化合物
EP1725562A1 (en) 2004-03-05 2006-11-29 Taisho Pharmaceutical Co., Ltd Pyrrolopyrimidine derivatives
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
KR100987870B1 (ko) 2005-07-29 2010-10-13 화이자 프로덕츠 인코포레이티드 피롤로[2,3-d]피리미딘 유도체, 이들의 중간체 및 합성
KR20080063809A (ko) 2005-09-30 2008-07-07 버텍스 파마슈티칼스 인코포레이티드 야누스 키나아제의 억제제로서 유용한 데아자퓨린
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CN101395134B (zh) * 2006-03-02 2011-08-31 安斯泰来制药有限公司 17β-羟类固醇脱氢酶5型抑制剂
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
CA2733359C (en) * 2008-08-20 2014-08-05 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds

Also Published As

Publication number Publication date
ECSP12011855A (es) 2012-06-29
UY32947A (es) 2011-05-31
MA33670B1 (fr) 2012-10-01
CN102574860A (zh) 2012-07-11
AU2010308028A1 (en) 2012-04-19
JP5629324B2 (ja) 2014-11-19
DOP2012000080A (es) 2012-06-15
AR078635A1 (es) 2011-11-23
TWI398444B (zh) 2013-06-11
WO2011045702A1 (en) 2011-04-21
MX2012004379A (es) 2012-06-01
TN2012000146A1 (fr) 2013-09-19
CA2776028A1 (en) 2011-04-21
JP2013508266A (ja) 2013-03-07
TW201125866A (en) 2011-08-01
IL218802A0 (en) 2012-06-28
EP2488524B1 (en) 2013-07-03
CL2012000795A1 (es) 2012-09-07
US20110136765A1 (en) 2011-06-09
US8633206B2 (en) 2014-01-21
CR20120164A (es) 2012-11-07
EP2488524A1 (en) 2012-08-22
KR20120083452A (ko) 2012-07-25
NI201200053A (es) 2012-08-09
ZA201202718B (en) 2012-12-27
ES2426407T3 (es) 2013-10-23
AP2012006192A0 (en) 2012-04-30
PE20121077A1 (es) 2012-08-10
CU20120059A7 (es) 2012-06-29
CA2776028C (en) 2015-12-01
CO6531451A2 (es) 2012-09-28
EA201290147A1 (ru) 2012-11-30

Similar Documents

Publication Publication Date Title
IN2012DN02577A (lt)
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
IL278119B (en) Disubstituted pyrazolo[5.1–a]pyrimidine compounds as trk kinase inhibitors
ME01269B (me) Jedinjenja pirolo (2,3-d) pirimidina
PH12015501779A1 (en) Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
MX363715B (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
MX2012007175A (es) Derivados de imidazopiridina como inhibidores de jak.
TN2011000245A1 (en) Organic compounds
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
WO2013004995A8 (en) Pyrimidinone compounds and their use
JO2822B1 (en) Inhibitors of the enzyme kinase P70 S6 and AKT
LT2658844T (lt) Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių
TW200745102A (en) Pyrido[2,3-d]pyrimidine derivatives, preparation thereof, therapeutic use thereof
CY1115106T1 (el) Ενωσεις πυρρολο[2,3-d]πυριμιδινης